Oruka Therapeutics (ORKA) risk factors
Item 1A of every Oruka Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors53 risks7 new2 dropped20 reworded
Oruka Therapeutics advanced its clinical pipeline, updating trial statuses for lead candidates ORKA-001 and ORKA-002 in psoriasis and other indications.
Filed Mar 12, 2026 - FY2024 10-K risk factors48 risks
Oruka Therapeutics faces high clinical development risk, relying heavily on its two most advanced programs, ORKA-001 and ORKA-002, targeting PsO. The company depends heavily on external licensing partnerships like Paragon and must protect its intellectual property across a competitive biopharmaceutical landscape. Financial dilution, capital requirements, and strict regulatory and pricing hurdles also dominate its risk profile.
Filed Mar 06, 2025